Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cadonilimab;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   Qian Chu;   Akeso Pharmaceuticals, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials